---
created: 2025-04-13
updated: 2025-04-13T10:53
id: j8+rrX.Mq*
specialty: immuno
specialty_id: 173
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies::ipilimumab
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies::pembrolizumab
  - "source/ak-step1-v11:": 
  - theme/firstaid::04-pathology::03-neoplasia::05-immune-checkpoint-interactions
  - "source/ak-step1-v11:": 
  - theme/firstaid::04-pathology::03-neoplasia::05-immune-checkpoint-interactions::ipilimumab
  - "source/ak-step1-v11:": 
  - theme/firstaid::04-pathology::03-neoplasia::05-immune-checkpoint-interactions::pembrolizumab
  - "source/ak-step1-v11:": 
  - source/ome-banner
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::08-antineoplastics::cancer-immunotherapy
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::16000-16999::16895
  - source/ak-step1-v11::$ankingupdates::$errata::bonus
  - source/ak-step1-v11::^other::^expn::bgadd
  - source/ak-step1-v11::^other::^fa-updates::fa2018
  - source/ak-step1-v11::^other::^highyield::3-highyield-temporary"
type: flashcard
---

# Question
Ipilimumab and Pembrolizumab are monoclonal antibodies that work by downregulating **immune tolerance** mechanisms   *bonus: their respective targets:

---

# Answer
- Ipilimumab = immunotherapy = targets CTLA-4 (normally functions in turning off cytotoxic T cells, helps anti-cancer T cells to avoid cancer immune escape)   - Pembrolizumab (and Nivolumab) binds PD-1, preventing PD-L1 on cancer cells from inactivating anti-cancer T cells